Evaxion slides after Merck opts out of gonorrhea vaccine licensing agreement

Evaxion A/S

19/12/2025 15:50

Updates

** Shares of Denmark-based drug developer Evaxion EVAX.O fall 9.4% to $5.21

** Says Merck & Co MRK.N will not exercise its option to license Evaxion's experimental gonorrhea vaccine, EVX-B2, leaving EVAX with global rights to the program

** Evaxion says it will look for another potential licensing partner

     ** Earlier this year, Merck exercised its option on a separate Evaxion vaccine candidate, EVX-B3, under a deal that could bring Evaxion up to $592 million in milestone payments plus royalties

** Evaxion added that Merck's decision does not affect its cash runway, which extends into H2 2027

** Including session moves, EVAX up 25.4% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))